Long-term Outcomes of Antiviral Therapy in Patients With Advanced Chronic HBV Infection

Soul Study Group

Research output: Contribution to journalShort survey

Abstract

Hepatitis B virus (HBV) suppression with nucleot(s)ide analogue therapy reduces the risk of hepatic decompensation and hepatocellular carcinoma (HCC) in patients with advanced liver disease.1 In the present era of potent antiviral therapies, the prognostic significance of the serum HBV DNA level as a biological gradient has substantially diminished; the majority of treated patients achieve virologic suppression.2,3 After control of viremia, a higher baseline fibrosis level is a useful predictor for disease progression.4 Few “prospective” studies on the effects of antiviral agents, especially in chronic hepatitis B (CHB) patients with advanced liver disease, have been reported.

Original languageEnglish
Pages (from-to)2811-2813.e1
JournalClinical Gastroenterology and Hepatology
Volume17
Issue number13
DOIs
Publication statusPublished - 2019 Dec

Fingerprint

Chronic Hepatitis B
Virus Diseases
Hepatitis B virus
Antiviral Agents
Liver
Viremia
Liver Diseases
Hepatocellular Carcinoma
Fibrosis
Therapeutics
Prospective Studies
DNA
Serum

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Long-term Outcomes of Antiviral Therapy in Patients With Advanced Chronic HBV Infection. / Soul Study Group.

In: Clinical Gastroenterology and Hepatology, Vol. 17, No. 13, 12.2019, p. 2811-2813.e1.

Research output: Contribution to journalShort survey

@article{aef45c37905b446e9a736068d406cd6b,
title = "Long-term Outcomes of Antiviral Therapy in Patients With Advanced Chronic HBV Infection",
abstract = "Hepatitis B virus (HBV) suppression with nucleot(s)ide analogue therapy reduces the risk of hepatic decompensation and hepatocellular carcinoma (HCC) in patients with advanced liver disease.1 In the present era of potent antiviral therapies, the prognostic significance of the serum HBV DNA level as a biological gradient has substantially diminished; the majority of treated patients achieve virologic suppression.2,3 After control of viremia, a higher baseline fibrosis level is a useful predictor for disease progression.4 Few “prospective” studies on the effects of antiviral agents, especially in chronic hepatitis B (CHB) patients with advanced liver disease, have been reported.",
author = "{Soul Study Group} and Lee, {Hye Won} and Park, {Jun Yong} and Kim, {Sang Gyune} and Tak, {Won Young} and Yim, {Hyung Joon} and Jang, {Byoung Kuk} and Kim, {Moon Young} and Kim, {Byung Ik} and Lee, {Jin Woo} and Yoon, {Ki Tae} and Cheong, {Jae Youn} and Kwon, {So Young} and Kim, {Tae Yeob} and Bae, {Si Hyun} and Seo, {Yeon Seok} and Kwon, {Jung Hyun} and Kim, {Dong Joon} and Kim, {Ja Kyung} and Jeong, {Soung Won} and Sungmin Myoung and Ahn, {Sang Hoon} and Han, {Kwang Hyub}",
year = "2019",
month = "12",
doi = "10.1016/j.cgh.2019.01.044",
language = "English",
volume = "17",
pages = "2811--2813.e1",
journal = "Clinical Gastroenterology and Hepatology",
issn = "1542-3565",
publisher = "W.B. Saunders Ltd",
number = "13",

}

TY - JOUR

T1 - Long-term Outcomes of Antiviral Therapy in Patients With Advanced Chronic HBV Infection

AU - Soul Study Group

AU - Lee, Hye Won

AU - Park, Jun Yong

AU - Kim, Sang Gyune

AU - Tak, Won Young

AU - Yim, Hyung Joon

AU - Jang, Byoung Kuk

AU - Kim, Moon Young

AU - Kim, Byung Ik

AU - Lee, Jin Woo

AU - Yoon, Ki Tae

AU - Cheong, Jae Youn

AU - Kwon, So Young

AU - Kim, Tae Yeob

AU - Bae, Si Hyun

AU - Seo, Yeon Seok

AU - Kwon, Jung Hyun

AU - Kim, Dong Joon

AU - Kim, Ja Kyung

AU - Jeong, Soung Won

AU - Myoung, Sungmin

AU - Ahn, Sang Hoon

AU - Han, Kwang Hyub

PY - 2019/12

Y1 - 2019/12

N2 - Hepatitis B virus (HBV) suppression with nucleot(s)ide analogue therapy reduces the risk of hepatic decompensation and hepatocellular carcinoma (HCC) in patients with advanced liver disease.1 In the present era of potent antiviral therapies, the prognostic significance of the serum HBV DNA level as a biological gradient has substantially diminished; the majority of treated patients achieve virologic suppression.2,3 After control of viremia, a higher baseline fibrosis level is a useful predictor for disease progression.4 Few “prospective” studies on the effects of antiviral agents, especially in chronic hepatitis B (CHB) patients with advanced liver disease, have been reported.

AB - Hepatitis B virus (HBV) suppression with nucleot(s)ide analogue therapy reduces the risk of hepatic decompensation and hepatocellular carcinoma (HCC) in patients with advanced liver disease.1 In the present era of potent antiviral therapies, the prognostic significance of the serum HBV DNA level as a biological gradient has substantially diminished; the majority of treated patients achieve virologic suppression.2,3 After control of viremia, a higher baseline fibrosis level is a useful predictor for disease progression.4 Few “prospective” studies on the effects of antiviral agents, especially in chronic hepatitis B (CHB) patients with advanced liver disease, have been reported.

UR - http://www.scopus.com/inward/record.url?scp=85075205037&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075205037&partnerID=8YFLogxK

U2 - 10.1016/j.cgh.2019.01.044

DO - 10.1016/j.cgh.2019.01.044

M3 - Short survey

C2 - 30731195

AN - SCOPUS:85075205037

VL - 17

SP - 2811-2813.e1

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

SN - 1542-3565

IS - 13

ER -